Drugs / ASP1948
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04094506 | Oct 2019 → Feb 2022 | cancer of unknown primary site | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT03565445 | Jul 2018 → Mar 2023 | cancer | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP1948 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04094506 ↗ |
| Known as | PTZ-329 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650444 ↗ |
| Route | Intravenous | “Intravenously (IV)” NCT03565445 ↗ |